Pranoti Mandrekar1, Ramon Bataller2, Hidekazu Tsukamoto3, Bin Gao4. 1. Department of Medicine, University of Massachusetts Medical School, Worcester, MA. Pranoti.Mandrekar@umassmed.edu. 2. Division of Gastroenterology and Hepatology, Departments of Medicine and Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC. ramon_bataller@med.unc.edu. 3. Southern California Research Center for ALPD and Cirrhosis and Department of Pathology, University of Southern California, Greater Los Angeles Department of Veterans Affairs Healthcare System, Los Angeles, CA. htsukamo@med.usc.edu. 4. Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD. bgao@mail.nih.gov.
Abstract
UNLABELLED: Alcoholic liver disease is a leading cause of liver-related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease. AH is characterized by an abrupt development of jaundice and complications related to liver insufficiency and portal hypertension in patients with heavy alcohol intake. The mortality of patients with AH is very high (20%-50% at 3 months). Available therapies are not effective in many patients, and targeted approaches are imminently needed. The development of such therapies requires translational studies in human samples and suitable animal models that reproduce the clinical and histological features of AH. In recent years, new animal models that simulate some of the features of human AH have been developed, and translational studies using human samples have identified potential pathogenic factors and histological parameters that predict survival. CONCLUSION: This review summarizes the unmet needs for translational studies on the pathogenesis of AH, preclinical translational tools, and emerging drug targets to benefit the AH patient. (Hepatology 2016;64:1343-1355).
UNLABELLED: Alcoholic liver disease is a leading cause of liver-related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease. AH is characterized by an abrupt development of jaundice and complications related to liver insufficiency and portal hypertension in patients with heavy alcohol intake. The mortality of patients with AH is very high (20%-50% at 3 months). Available therapies are not effective in many patients, and targeted approaches are imminently needed. The development of such therapies requires translational studies in human samples and suitable animal models that reproduce the clinical and histological features of AH. In recent years, new animal models that simulate some of the features of humanAH have been developed, and translational studies using human samples have identified potential pathogenic factors and histological parameters that predict survival. CONCLUSION: This review summarizes the unmet needs for translational studies on the pathogenesis of AH, preclinical translational tools, and emerging drug targets to benefit the AHpatient. (Hepatology 2016;64:1343-1355).
Authors: Pau Sancho-Bru; José Altamirano; Daniel Rodrigo-Torres; Mar Coll; Cristina Millán; Juan José Lozano; Rosa Miquel; Vicente Arroyo; Juan Caballería; Pere Ginès; Ramon Bataller Journal: Hepatology Date: 2012-04-23 Impact factor: 17.425
Authors: Irina A Kirpich; Natalia V Solovieva; Svetlana N Leikhter; Natalia A Shidakova; Oxsana V Lebedeva; Pavel I Sidorov; Tatjana A Bazhukova; Andrej G Soloviev; Shirish S Barve; Craig J McClain; Matt Cave Journal: Alcohol Date: 2008-12 Impact factor: 2.405
Authors: Siddharth Singh; Mohammad Hassan Murad; Apoorva K Chandar; Connie M Bongiorno; Ashwani K Singal; Stephen R Atkinson; Mark R Thursz; Rohit Loomba; Vijay H Shah Journal: Gastroenterology Date: 2015-06-16 Impact factor: 22.682
Authors: Paulius V Kuprys; Hidekazu Tsukamoto; Bin Gao; Lin Jia; Jacob McGowan; Craig M Coopersmith; Maria Camargo Moreno; Holly Hulsebus; Avtar S Meena; Flavia M Souza-Smith; Philip Roper; Michelle T Foster; S Vamsee Raju; S Alex Marshall; Mayumi Fujita; Brenda J Curtis; Todd A Wyatt; Pranoti Mandrekar; Elizabeth J Kovacs; Mashkoor A Choudhry Journal: Alcohol Date: 2018-08-24 Impact factor: 2.405
Authors: Jun Xu; Hsiao-Yen Ma; Xiao Liu; Sara Rosenthal; Jacopo Baglieri; Ryan McCubbin; Mengxi Sun; Yukinori Koyama; Cedric G Geoffroy; Kaoru Saijo; Linshan Shang; Takahiro Nishio; Igor Maricic; Max Kreifeldt; Praveen Kusumanchi; Amanda Roberts; Binhai Zheng; Vipin Kumar; Karsten Zengler; Donald P Pizzo; Mojgan Hosseini; Candice Contet; Christopher K Glass; Suthat Liangpunsakul; Hidekazu Tsukamoto; Bin Gao; Michael Karin; David A Brenner; George F Koob; Tatiana Kisseleva Journal: JCI Insight Date: 2020-02-13